Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT® in brain cancer patients

Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT belonging to Curasight's treatment platform. Initiation of the study marks a key milestone with Curasight now in clinical development with both its diagnostic (uTRACE®) and...